He and Matt talk about portfolio construction, and the dynamics of taking on the right capital structure throughout different phases of a company's lifecycle. Neil shares early learnings from the commercial launch of Attruby, how being a commercial stage company can impact culture, and why he created the early-stage R&D focused sister company Gondola. Plus, discussing talent, intellectual property, and more. Chapters The hub and spoke model - 0:41 Equity structure - 5:43 Putt

He describes the label and what he believes it means for the therapy's competitive position. Plus, the commercial plans that have put...

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.

BridgeBio's Neil Kumar shares experiences that may be good learnings for other drug developers and discusses his company's unique model.